Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Public ClinicalTrials.gov record NCT07446998. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the effect of enobosarm on total body weight
Study identification
- NCT ID
- NCT07446998
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 65 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2026
- Primary completion
- Sep 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Jun 30, 2026
2026 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| DM Clinical Research - Phoenix | Phoenix | Arizona | 85012 | Recruiting |
| DM Clinical Research - MIA | Doral | Florida | 33166 | Recruiting |
| Universal Axon Clinical Research (Rovia - UACR) | Doral | Florida | 33166 | Recruiting |
| Paramo Health | Miami | Florida | 33175 | Recruiting |
| IMIC Research a Rovia Clinical Research Company | Miami | Florida | 33176 | Recruiting |
| Paramo Health | Miami | Florida | 33176 | Recruiting |
| UD Research | Atlanta | Georgia | 30342 | Withdrawn |
| Pennington Biomedical Research Center | Baton Rouge | Louisiana | 70808 | Recruiting |
| Centennial Medical Group (CMG) | Columbia | Maryland | 21045 | Recruiting |
| SKY Integrative Medical Center | Ridgeland | Mississippi | 39157 | Recruiting |
| ALSA Research | New York | New York | 10016 | Recruiting |
| Coastal Research Institute, LLC | Fayetteville | North Carolina | 28304 | Recruiting |
| DM Clinical - Dallas | Irving | Texas | 75061 | Recruiting |
| DM Clinical - Seattle | Seattle | Washington | 98122 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07446998, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07446998 live on ClinicalTrials.gov.